146 related articles for article (PubMed ID: 33788764)
1. First-line Gemcitabine
Yamamoto S; Narui K; Ishikawa T; Adachi S; Shimada K; Shimizu D; Yamada A; Sugae S; Tanabe M; Oba M; Morita S; Doi T; Hasegawa S; Morita T; Kito A; Chishima T; Ichikawa Y; Endo I;
Anticancer Res; 2021 Mar; 41(3):1671-1676. PubMed ID: 33788764
[TBL] [Abstract][Full Text] [Related]
2. Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.
Twelves C; Cortés J; O'Shaughnessy J; Awada A; Perez EA; Im SA; Gómez-Pardo P; Schwartzberg LS; Diéras V; Yardley DA; Potter DA; Mailliez A; Moreno-Aspitia A; Ahn JS; Zhao C; Hoch U; Tagliaferri M; Hannah AL; Rugo HS
Eur J Cancer; 2017 May; 76():205-215. PubMed ID: 28360015
[TBL] [Abstract][Full Text] [Related]
3. Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.
Park YH; Im SA; Kim SB; Sohn JH; Lee KS; Chae YS; Lee KH; Kim JH; Im YH; Kim JY; Kim TY; Lee KH; Ahn JH; Kim GM; Park IH; Lee SJ; Han HS; Kim SH; Jung KH;
Eur J Cancer; 2017 Nov; 86():385-393. PubMed ID: 29100193
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of gemcitabine in combination with vinorelbine versus gemcitabine followed by vinorelbine for metastatic breast cancer.
Park IH; Ro J; Lee KS; Kim SN; Yun YH; Nam BH
Invest New Drugs; 2010 Oct; 28(5):659-69. PubMed ID: 19575146
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of gemcitabine and carboplatin in metastatic breast cancers with prior exposure to anthracyclines and taxanes.
Chan D; Yeo WL; Tiemsim Cordero M; Wong CI; Chuah B; Soo R; Tan SH; Lim SE; Goh BC; Lee SC
Invest New Drugs; 2010 Dec; 28(6):859-65. PubMed ID: 19705063
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial.
Martín M; Ruiz A; Muñoz M; Balil A; García-Mata J; Calvo L; Carrasco E; Mahillo E; Casado A; García-Saenz JA; Escudero MJ; Guillem V; Jara C; Ribelles N; Salas F; Soto C; Morales-Vasquez F; Rodríguez CA; Adrover E; Mel JR;
Lancet Oncol; 2007 Mar; 8(3):219-25. PubMed ID: 17329192
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial.
Blackstein M; Vogel CL; Ambinder R; Cowan J; Iglesias J; Melemed A
Oncology; 2002; 62(1):2-8. PubMed ID: 11810037
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer.
Kontopodis E; Kentepozidis N; Christophyllakis Ch; Boukovinas I; Kalykaki A; Kalbakis K; Vamvakas L; Agelaki S; Kotsakis A; Vardakis N; Georgoulias V; Mavroudis D
Cancer Chemother Pharmacol; 2015 Jan; 75(1):153-60. PubMed ID: 25398698
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.
Krop IE; Kim SB; Martin AG; LoRusso PM; Ferrero JM; Badovinac-Crnjevic T; Hoersch S; Smitt M; Wildiers H
Lancet Oncol; 2017 Jun; 18(6):743-754. PubMed ID: 28526538
[TBL] [Abstract][Full Text] [Related]
10. [Clinical experience with gemcitabine treatment for metastatic breast cancer].
Watanabe M; Hara F; Kiyoto S; Takahashi M; Takabatake D; Takashima S; Aogi K; Ohsumi S
Gan To Kagaku Ryoho; 2013 Oct; 40(10):1355-9. PubMed ID: 24105058
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer.
Rha SY; Moon YH; Jeung HC; Kim YT; Sohn JH; Yang WI; Suh CO; Kim GE; Roh JK; Chung HC
Breast Cancer Res Treat; 2005 Apr; 90(3):215-21. PubMed ID: 15830134
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II study of gemcitabine plus mitoxantrone as salvage chemotherapy in metastatic breast cancer.
Lorusso V; Crucitta E; Silvestris N; Catino A; Caporusso L; Mazzei A; Guida M; Latorre A; Sambiasi D; D'Amico C; Schittulli F; Calabrese P; De Lena M
Br J Cancer; 2003 Feb; 88(4):491-5. PubMed ID: 12592360
[TBL] [Abstract][Full Text] [Related]
13. Evidence for in vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer.
Alexopoulos A; Tryfonopoulos D; Karamouzis MV; Gerasimidis G; Karydas I; Kandilis K; Stavrakakis J; Stavrinides H; Georganta C; Ardavanis A; Rigatos G
Ann Oncol; 2004 Jan; 15(1):95-9. PubMed ID: 14679126
[TBL] [Abstract][Full Text] [Related]
14. First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study.
Feher O; Vodvarka P; Jassem J; Morack G; Advani SH; Khoo KS; Doval DC; Ermisch S; Roychowdhury D; Miller MA; von Minckwitz G
Ann Oncol; 2005 Jun; 16(6):899-908. PubMed ID: 15821120
[TBL] [Abstract][Full Text] [Related]
15. Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial.
Robson M; Ruddy KJ; Im SA; Senkus E; Xu B; Domchek SM; Masuda N; Li W; Tung N; Armstrong A; Delaloge S; Bannister W; Goessl C; Degboe A; Hettle R; Conte P
Eur J Cancer; 2019 Oct; 120():20-30. PubMed ID: 31446213
[TBL] [Abstract][Full Text] [Related]
16. A comparison of toxicity and health care resource use between eribulin, capecitabine, gemcitabine, and vinorelbine in patients with metastatic breast cancer treated in a community oncology setting.
Dranitsaris G; Beegle N; Kalberer T; Blau S; Cox D; Faria C
J Oncol Pharm Pract; 2015 Jun; 21(3):170-7. PubMed ID: 24620009
[TBL] [Abstract][Full Text] [Related]
17. Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group.
Mavroudis D; Malamos N; Alexopoulos A; Kourousis C; Agelaki S; Sarra E; Potamianou A; Kosmas C; Rigatos G; Giannakakis T; Kalbakis K; Apostolaki F; Vlachonicolis J; Kakolyris S; Samonis G; Georgoulias V
Ann Oncol; 1999 Feb; 10(2):211-5. PubMed ID: 10093691
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine plus doxorubicin as first-line treatment in advanced or metastatic breast cancer (MBC), a phase II study.
El Serafi MM; El Khodary AI; El Zawahry HR; Mansour OM; Gaballa HE
J Egypt Natl Canc Inst; 2006 Sep; 18(3):209-15. PubMed ID: 17671530
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine for the treatment of metastatic breast cancer.
Jones J; Takeda A; Tan SC; Cooper K; Loveman E; Clegg A
Health Technol Assess; 2009 Sep; 13 Suppl 2():1-7. PubMed ID: 19804683
[TBL] [Abstract][Full Text] [Related]
20. Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial.
Perez EA; Awada A; O'Shaughnessy J; Rugo HS; Twelves C; Im SA; Gómez-Pardo P; Schwartzberg LS; Diéras V; Yardley DA; Potter DA; Mailliez A; Moreno-Aspitia A; Ahn JS; Zhao C; Hoch U; Tagliaferri M; Hannah AL; Cortes J
Lancet Oncol; 2015 Nov; 16(15):1556-1568. PubMed ID: 26482278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
